Evidence map›Paper›PMID 42737867›Full record

ArticleInternational journal of molecular sciences2026

Cardiac Glycoside 3β-Bufalin Suppresses Cancer Cell Proliferation by Coupling with Na

Takuto Fujii, Takahiro Shimizu, Yasuharu Shimizu, Mizuki Katoh, Tomoyuki Okumura, Tsutomu Fujii, Hideki Sakai

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Takuto FujiiDepartment of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-0547-1691
Takahiro ShimizuDepartment of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-4408-7828
Yasuharu ShimizuTokyo Research Center, Kyushin Pharmaceutical Co., Ltd., Tokyo 166-0012, Japan.
Mizuki KatohDepartment of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Tomoyuki OkumuraDepartment of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.
Tsutomu FujiiDepartment of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0003-0625-1911
Hideki SakaiDepartment of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.ORCID 0000-0002-9753-7941

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bufadienolides are toad-derived cardiotonic steroids with anti-cancer activity; however, their Na

Indexed as

Antineoplastic AgentsBufanolidesCardiac GlycosidesMembrane MicrodomainsSodium-Potassium-Exchanging ATPaseCell Line, TumorCell ProliferationHT29 CellsHumansAntineoplastic AgentsbufalinBufanolidesCardiac GlycosidesSodium-Potassium-Exchanging ATPasebufadienolidebufalincancermembrane microdomainNa+,K+-ATPasevolume-regulated anion channel

Identifiers

PMID42737867
PMCPMC13565899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.